PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NWBO vs. DNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Performance

NWBO vs. DNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Northwest Biotherapeutics, Inc. (NWBO) and Ginkgo Bioworks Holdings, Inc. (DNA). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-40.10%
-79.39%
NWBO
DNA

Returns By Period

In the year-to-date period, NWBO achieves a -60.64% return, which is significantly higher than DNA's -90.64% return.


NWBO

YTD

-60.64%

1M

-8.17%

6M

-40.11%

1Y

-66.40%

5Y (annualized)

4.15%

10Y (annualized)

-25.31%

DNA

YTD

-90.64%

1M

-28.72%

6M

-79.34%

1Y

-89.59%

5Y (annualized)

N/A

10Y (annualized)

N/A

Fundamentals


NWBODNA
Market Cap$386.95M$366.14M
EPS-$0.07-$12.89
Total Revenue (TTM)$1.24M$217.95M

Key characteristics


NWBODNA
Sharpe Ratio-1.05-0.90
Sortino Ratio-2.26-2.29
Omega Ratio0.770.76
Calmar Ratio-0.68-0.90
Martin Ratio-1.41-1.40
Ulcer Index48.03%63.92%
Daily Std Dev64.43%99.34%
Max Drawdown-99.99%-99.10%
Current Drawdown-99.98%-98.94%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.1

The correlation between NWBO and DNA is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Risk-Adjusted Performance

NWBO vs. DNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NWBO, currently valued at -1.05, compared to the broader market-4.00-2.000.002.004.00-1.05-0.90
The chart of Sortino ratio for NWBO, currently valued at -2.26, compared to the broader market-4.00-2.000.002.004.00-2.26-2.29
The chart of Omega ratio for NWBO, currently valued at 0.77, compared to the broader market0.501.001.502.000.770.76
The chart of Calmar ratio for NWBO, currently valued at -0.78, compared to the broader market0.002.004.006.00-0.78-0.90
The chart of Martin ratio for NWBO, currently valued at -1.41, compared to the broader market-10.000.0010.0020.0030.00-1.41-1.40
NWBO
DNA

The current NWBO Sharpe Ratio is -1.05, which is comparable to the DNA Sharpe Ratio of -0.90. The chart below compares the historical Sharpe Ratios of NWBO and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-1.20-1.00-0.80-0.60-0.40-0.20JuneJulyAugustSeptemberOctoberNovember
-1.05
-0.90
NWBO
DNA

Dividends

NWBO vs. DNA - Dividend Comparison

Neither NWBO nor DNA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

NWBO vs. DNA - Drawdown Comparison

The maximum NWBO drawdown since its inception was -99.99%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for NWBO and DNA. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%-75.00%JuneJulyAugustSeptemberOctoberNovember
-85.87%
-98.94%
NWBO
DNA

Volatility

NWBO vs. DNA - Volatility Comparison

The current volatility for Northwest Biotherapeutics, Inc. (NWBO) is 21.02%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 27.50%. This indicates that NWBO experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%JuneJulyAugustSeptemberOctoberNovember
21.02%
27.50%
NWBO
DNA

Financials

NWBO vs. DNA - Financials Comparison

This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items